Navigation Links
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Date:4/22/2009

nd electrolyte loss at a dose of 200x3mg/week, no clinically relevant drug-related adverse events or changes in laboratory parameters were observed. AEZS-112 was shown to be metabolically stable in human plasma. As predicted by pharmacokinetic modelling based on data from part I of the study, the split-dose scheme leads to a higher Cmax and trough values after administration of comparable doses.

Conclusions

    - AEZS-112 was well tolerated over repeated treatment courses;
    - So far, a maximum tolerated dose for weekly dosing has not been
      defined; and
    - Prolonged courses of stable disease in both parts of the study are an
      encouraging observation.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional i
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... PRINCETON, N.J. , July 24, 2014 /PRNewswire/ ... largest provider of regulatory and ethical review services ... acquired Alliance Biosciences. Formerly a division of ... Biosciences was the leading biosafety and biosecurity consulting ... . With this addition, WCG,s biosafety division – ...
(Date:7/24/2014)... 24, 2014 Draper University, a ... proud to announce that for 6 weeks this ... will converge on the Draper University campus in ... experiential program focused on entrepreneurship, building real-world skills, ... currently running its sixth cohort, continues to refresh ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
Breaking Biology Technology:3 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Recurring Disposables, Services and Accessories Revenue Up ... Catheter Launch Provided, ST. LOUIS, March 3 ... fourth quarter and full year,ended December 31, 2007., ... $39.3 million,compared with $27.2 million in 2006. Sales of ...
... Rochelle, NY, February 29, 2008 miRNA research ... in the life science world, reports Genetic Engineering ... are studying the effects of over- or underexpression ... of pathogenesis in a variety of diseases, according ...
... 29 DW Healthcare Partners (DWHP),a healthcare ... sale of one,of its portfolio companies, NWT ... Holdings (LabCorp(R)), one of the world,s largest,clinical ... UT, Tandem,Labs is a leading bioanalytical and ...
Cached Biology Technology:Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
(Date:7/25/2014)... detected an unknown interaction between microorganisms and salt. When ... droplet of salt water and is left to dry, ... biosaline 3D morphologically complex formations, where they hibernate. Afterwards, ... discovery was made by chance with a home microscope, ... journal and may help to find signs of ...
(Date:7/24/2014)... loss leads to conflict among people around the world, ... (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) Program ... to tackle global biodiversity decline. , The harvest of ... people and provides protein for more than a billion ... surprise that today,s unprecedented loss of wildlife, is bringing ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Bacteria manipulate salt to build shelters to hibernate 2New study draws links between wildlife loss and social conflicts 2
... PARTEQ Innovations, the technology commercialization office of Queen,s ... federal government towards the establishment of a National ... of Green Chemistry technologies. The first ... Canada will bring together Canada,s leading Green Chemistry ...
... of London have discovered how changes to a frog,s immune ... which is devastating frog populations across the UK. ... by a foreign virus which is estimated to be killing ... When it strikes garden ponds, the surrounding lawn becomes strewn ...
... p53 protects against cancer and is usually described as ... at the Swedish medical university Karolinska Institutet have now ... activity of p53. As the regulation mechanism is relatively ... the mystery of cancer. The p53 gene makes ...
Cached Biology News:Queen's receives $9.1 million to establish National Center of Excellence in green chemistry 2Queen's receives $9.1 million to establish National Center of Excellence in green chemistry 3Frog's immune system is key in fight against killer virus 2Newly discovered gene plays vital role in cancer 2
Request Info...
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
Biology Products: